Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
Steve SHEN
Steve SHEN
Positions:

CEO

Company:

Convalife (Shanghai) Co., Ltd.

Dr. Shen Xiaokun, CEO of Convalife Pharmaceutical Co., Ltd., graduated from Wuhan University with degrees in clinical medicine and Bioscience, and obtained Ph.D degree in pharmacology from Shanghai Institute of Materia Medica, CAS. Dr. Shen has been engaged in the research and development of new drugs for small molecules and antibodies in Hengrui, Novartis and other well-known enterprises. Dr. Shen has more than 10 years of experience in the research and development of new drugs. He has led and participated ~10 projects in the clinical development of new drugs in the fields of anti-tumor, immunity, dermatology and other diseases. He has also helped several drugs to be successfully NDA in China, including first in class IL-17 antibody, Cosentyx, etc. Convalife originated from Latin “valere”, meaning “value and strong”Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies for cancer, autoimmune and infectious diseases to patients in China and around the world. Convalife develops new therapies with the potential of 'first in class' and 'best in class', and has strong new drug R & D and clinical development capabilities. Convalife obtained investment of famous listed companies such as Wuxibiologics (HK. 02269), Menovo Pharmaceutical (603538) etc.